Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by Remington, G. Articles by Kapur, S. Search for Related Content PubMed Citation Articles by Remington, G. Articles by Kapur, S. Atypical Neuroleptics Schizophrenia Spectrum Disorders PET Related Article

A PET Study Evaluating Dopamine D₂ Receptor Occupancy for Long-Acting Injectable Risperidone

OBJECTIVE: Long-acting injectable risperidone represents the first clinically available depot atypical antipsychotic. The present study used positron emission tomography (PET) to evaluate its dopamine D₂ binding profile at doses of 25, 50, or 75 mg administered every 2 weeks. METHOD: After achieving stabilization with one of the doses, nine patients with a diagnosis of schizophrenia or schizoaffective disorder underwent [¹¹C]raclopride PET to measure D₂ occupancy. Participants were scanned twice during the 2-week injection interval: within 3 days after injection (postinjection) and within 5 days before the next injection (preinjection). At the same time, plasma was collected for measurements of risperidone plus 9-hydroxyrisperidone. RESULTS: Mean post- and preinjection D₂ occupancy levels for the 25-, 50-, and 75-mg doses were 71.0% and 54.0%, 74.4% and 65.4%, and 81.5% and 75.0%, respectively. There was a significant correlation between dose and plasma concentrations of risperidone plus 9-hydroxyrisperidone, and the estimated plasma concentration associated with 50% D₂ occupancy (ED₅₀) was 11.06 ng/ml. Prolactin levels were not correlated with drug levels or D₂ occupancy. CONCLUSIONS: All three doses of injectable risperidone showed peak D₂ occupancy levels above the 65% threshold associated with optimal clinical response; the 75-mg dose approximated the 80% threshold linked to increased risk of extrapyramidal symptoms. Doses of 25 or 50 mg should provide therapeutic efficacy while minimizing the risk of extrapyramidal symptoms.

Related Article:

In This Issue
Am J Psychiatry 2006 163: A44. [Full Text] [PDF]

This article has been cited by other articles:

				C. Dolder, M. Nelson, and Z. Deyo Paliperidone for schizophrenia Am. J. Health Syst. Pharm., March 1, 2008; 65(5): 403 - 413. [Abstract] [Full Text] [PDF]

				C. A. Tamminga Practical Treatment Information for Schizophrenia Am J Psychiatry, April 1, 2006; 163(4): 563 - 565. [Full Text] [PDF]

Get information about faster international access.

Privacy Policy

Copyright © 2006 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us